Acadia Pharmaceuticals Inc.

ACAD Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of ACAD by members of U.S. Congress

Politician Type Traded
Chris Jacobs House / R Sale $1,001 - $15,000 Jun 16, 2022
Chris Jacobs House / R Sale $1,001 - $15,000 Sep 08, 2020
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Feb 19, 2019
Ro Khanna House / D Sale $1,001 - $15,000 May 08, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
ACAD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ACAD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ACAD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ACAD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $500,000 Jul 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $440,000 Apr 18, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $510,000 Jan 19, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $220,000 Oct 21, 2024 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues
  • $450,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $250,000 Apr 16, 2024 Issue: Medicare/Medicaid Health Issues
  • $240,000 Jan 19, 2024 Issue: Medicare/Medicaid Health Issues
  • $180,000 Oct 18, 2023 Issue: Medicare/Medicaid Health Issues
  • $230,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $370,000 Jan 19, 2023 Issue: Defense Budget/Appropriations Medicare/Medicaid Health Issues
  • $260,000 Oct 19, 2022 Issue: Defense Budget/Appropriations Medicare/Medicaid Health Issues
  • $310,000 Aug 18, 2022 Issue: None
  • $230,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $200,000 Jan 20, 2022 Issue: None
  • $210,000 Oct 19, 2021 Issue: None
  • $210,000 Jul 19, 2021 Issue: None
  • $220,000 Apr 20, 2021 Issue: None
  • $190,000 Jan 20, 2021 Issue: None
  • $10,000 Oct 16, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $10,000 Jul 15, 2020 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Apr 16, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $20,000 Jan 21, 2020 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Oct 21, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Jul 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Apr 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Oct 22, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
Corporate Lobbying

Estimated quarterly lobbying spending

Revenue Breakdown

ACAD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
ACAD Income Statement
ACAD Balance Sheet
ACAD Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Compounds, salts thereof and methods for treatment of diseases Nov. 12, 2024
  • Patent Title: Agitation process for preparing a carbetocin drug product Dec. 19, 2023
  • Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c Dec. 12, 2023
  • Patent Title: Crystalline forms of trofinetide Nov. 28, 2023
  • Patent Title: Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis Oct. 11, 2022
  • Patent Title: Formulations of pimavanserin Sep. 27, 2022
  • Patent Title: Compounds, salts thereof and methods for treatment of diseases Sep. 13, 2022
  • Patent Title: Compounds, salts thereof and methods for treatment of diseases May. 31, 2022
  • Patent Title: Combination of pimavanserin and cytochrome p450 modulators Dec. 07, 2021
  • Patent Title: Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent Nov. 02, 2021
  • Patent Title: Pimavanserin for treating impulse control disorder Oct. 05, 2021
  • Patent Title: Compounds for pain treatment, compositions comprising same, and methods of using same Aug. 17, 2021
  • Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c Apr. 20, 2021
  • Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form Apr. 20, 2021
  • Patent Title: Combination of pimavanserin and cytochrome p450 modulators Mar. 23, 2021
  • Patent Title: Formulations of pimavanserin Dec. 01, 2020
  • Patent Title: Formulations of pimavanserin May. 12, 2020
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jan. 07, 2020
  • Patent Title: Combination of pimavanserin and cytochrome p450 modulators Dec. 31, 2019
  • Patent Title: Formulations of pimavanserin Oct. 22, 2019
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jul. 24, 2018
  • Patent Title: Methods of treatment using selective 5-ht2a inverse agonists Sep. 19, 2017
  • Patent Title: Methods for the treatment of parkinson's disease psychosis using pimavanserin Sep. 12, 2017
  • Patent Title: Muscarinic agonists Jun. 06, 2017
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 14, 2017
  • Patent Title: Tetrahydroquinoline analogues as muscarinic agonists Dec. 20, 2016
  • Patent Title: Methods for the treatment of parkinson's disease psychosis using pimavanserin Sep. 20, 2016
  • Patent Title: Azacyclic compounds Mar. 29, 2016
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 15, 2015
  • Patent Title: Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta Jun. 23, 2015
  • Patent Title: Combination of pimavanserin and risperidone for the treatment of psychosis Jun. 09, 2015
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 30, 2014
  • Patent Title: Compounds with activity at estrogen receptors Sep. 02, 2014
  • Patent Title: Tetrahydroquinoline analogues as muscarinic agonists Mar. 25, 2014
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 31, 2013
  • Patent Title: Compounds with activity at estrogen receptors Jun. 25, 2013
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 19, 2013
  • Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Aug. 07, 2012
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jul. 24, 2012
  • Patent Title: Compounds with activity at estrogen receptors Jan. 24, 2012
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Aug. 30, 2011
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Aug. 09, 2011
  • Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Apr. 12, 2011
  • Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Jan. 25, 2011
  • Patent Title: Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-y1)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation Jan. 11, 2011
  • Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Jan. 04, 2011
  • Patent Title: Compounds with activity at estrogen receptors Nov. 02, 2010
  • Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Oct. 26, 2010
  • Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Sep. 07, 2010
  • Patent Title: N-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Jun. 08, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

ACAD News

Recent insights relating to ACAD

CNBC Recommendations

Recent picks made for ACAD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ACAD

ACAD Analyst Ratings

ACAD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ACAD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ACAD stock a Buy, Sell, or Hold?

  • What is the price target for $ACAD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ACAD Top Shareholders
Shareholder
Shares Held
ACAD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ACAD stock?

  • Who owns the most shares of $ACAD stock?

  • What funds own $ACAD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ACAD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ACAD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top